WO2009054128A1 - 単球由来多能性細胞（ｍｏｍｃ）の効率的な作製法 - Google Patents

単球由来多能性細胞（ｍｏｍｃ）の効率的な作製法 Download PDF

Info

Publication number
WO2009054128A1
WO2009054128A1 PCT/JP2008/002990 JP2008002990W WO2009054128A1 WO 2009054128 A1 WO2009054128 A1 WO 2009054128A1 JP 2008002990 W JP2008002990 W JP 2008002990W WO 2009054128 A1 WO2009054128 A1 WO 2009054128A1
Authority
WO
WIPO (PCT)
Prior art keywords
momc
monocyte
multipotent cell
efficient production
derived multipotent
Prior art date
Application number
PCT/JP2008/002990
Other languages
English (en)
French (fr)
Inventor
Masataka Kuwana
Takashi Kato
Noriyuki Seta
Hiroshi Miyazaki
Original Assignee
Keio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keio University filed Critical Keio University
Priority to US12/738,997 priority Critical patent/US8216838B2/en
Priority to EP08843082A priority patent/EP2202295A4/en
Publication of WO2009054128A1 publication Critical patent/WO2009054128A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Botany (AREA)

Abstract

　本発明は、臓器再生のための細胞移植に非常に適した多能性細胞であるＭＯＭＣを効率よく、大量に作製しうる実用的な方法を提供することを目的とする。本発明者らは、フィブロネクチン上での末梢血単球のインビトロ培養をＳＤＦ－１存在下で行うことによって、より効率的にＭＯＭＣを作製し得ることを見い出し、本発明を完成するに至った。すなわち、本発明は、ＣＤ１４を発現する末梢血単球をフィブロネクチン上でインビトロ培養することによりＭＯＭＣを作製する方法であって、前記のインビトロ培養をＳＤＦ－１存在下で行うことを特徴とするＭＯＭＣの作製方法である。
PCT/JP2008/002990 2007-10-23 2008-10-22 単球由来多能性細胞（ｍｏｍｃ）の効率的な作製法 WO2009054128A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/738,997 US8216838B2 (en) 2007-10-23 2008-10-22 Method for efficient production of monocyte-derived multipotent cell (MOMC)
EP08843082A EP2202295A4 (en) 2007-10-23 2008-10-22 METHOD FOR EFFICIENT MANUFACTURE OF A MULTIPOTENTAL MONOCYTE CELL (MOMC)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007275461A JP5416895B2 (ja) 2007-10-23 2007-10-23 単球由来多能性細胞（ｍｏｍｃ）の効率的な作製法
JP2007-275461 2007-10-23

Publications (1)

Publication Number Publication Date
WO2009054128A1 true WO2009054128A1 (ja) 2009-04-30

Family

ID=40579236

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/002990 WO2009054128A1 (ja) 2007-10-23 2008-10-22 単球由来多能性細胞（ｍｏｍｃ）の効率的な作製法

Country Status (4)

Country Link
US (1) US8216838B2 (ja)
EP (1) EP2202295A4 (ja)
JP (1) JP5416895B2 (ja)
WO (1) WO2009054128A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5929111B2 (ja) * 2011-11-11 2016-06-01 Dic株式会社 接着細胞の培養方法及びそれに用いる細胞培養基材
EP3091084A1 (en) * 2015-05-08 2016-11-09 Université Catholique De Louvain Methods for assessing the purity of a mesenchymal stem cells preparation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004275145A (ja) * 2003-03-18 2004-10-07 Keio Gijuku 単球由来多能性細胞ｍｏｍｃ
US7101708B1 (en) * 1998-07-27 2006-09-05 Yeda Research And Development Co. Ltd. Hematopoietic cell composition for use in transplantation
JP2006333866A (ja) * 2005-06-02 2006-12-14 Eisho Ryu 自家幹細胞とその用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014214A1 (en) * 2005-01-11 2008-01-17 Mitchell Krathwohl Composition and Method for Inducing Protective Vaccine Response Using SDF-1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101708B1 (en) * 1998-07-27 2006-09-05 Yeda Research And Development Co. Ltd. Hematopoietic cell composition for use in transplantation
JP2004275145A (ja) * 2003-03-18 2004-10-07 Keio Gijuku 単球由来多能性細胞ｍｏｍｃ
JP2006333866A (ja) * 2005-06-02 2006-12-14 Eisho Ryu 自家幹細胞とその用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SETA N. ET AL.: "Hito Tankyu Yurai Tanosei Saibo no Yudo Katei no Kento", INFLAMMATION AND REGENERATION, vol. 27, no. 4, 1 July 2007 (2007-07-01), pages 334 *
SETA N. ET AL.: "Identification of molecular factors required for transdifferentiation of human circulating monocytes into multipotential cells.", BLOOD, vol. 110, no. 11,P 1, 16 November 2007 (2007-11-16), pages 710 - 711, XP008133007 *

Also Published As

Publication number Publication date
JP2009100679A (ja) 2009-05-14
US20100261202A1 (en) 2010-10-14
US8216838B2 (en) 2012-07-10
JP5416895B2 (ja) 2014-02-12
EP2202295A1 (en) 2010-06-30
EP2202295A4 (en) 2012-01-18

Similar Documents

Publication Publication Date Title
IN2012DN00462A (ja)
WO2008090770A1 (ja) Ｌ－アミノ酸を生産する微生物及びｌ－アミノ酸の製造法
WO2012094425A3 (en) Biological methods for preparing adipic acid
WO2007117765A3 (en) Ex vivo generated tissue system
WO2007002136A3 (en) Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells
WO2011011302A3 (en) Differentiation of human embryonic stem cells
WO2013022998A3 (en) Production of carboxylates and methane from biomass waste
EP2495311A4 (en) PROCESS FOR PRODUCING MESENCHYMAL STEM CELLS FROM HUMAN PLURIPOTENT STEM CELLS, AND MESENCHYMAL STEM CELLS THUS PRODUCED
WO2008153179A1 (ja) 脂肪組織由来多系統前駆細胞
WO2019014310A8 (en) Biological methods for preparing terpenes
WO2007120811A3 (en) Hemangio-colony forming cells
WO2009135074A3 (en) Microorganisms for the production of methacrylic acid
MX2012000110A (es) Metodo para producir eritrocitos sin celulas alimetadoras.
MX2011009269A (es) Fermentacion de biomasa para la produccion de etanol.
WO2007103282A3 (en) Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
EP2633036A4 (en) METHODS OF DIFFERENTIATION FOR THE PRODUCTION OF GLIAL CELL POPULATIONS
WO2009028338A1 (ja) 新規オキシダーゼ遺伝子、および該遺伝子を利用する３－インドールピルビン酸の製造方法
EA201390593A1 (ru) Способ и система для производства спиртов и/или кислот
WO2007143117A3 (en) Differentiation of primate pluripotent cells to hepatocyte-lineage cells
EA201390602A1 (ru) Способ и система для производства углеводородных продуктов
WO2008024769A3 (en) Intensified perfusion production method
IN2014CN03196A (ja)
CA2862554A1 (en) Improved carbon capture in fermentation
MX2010004397A (es) Celula para uso en la produccion de proteina exogena y proceso de produccion que utiliza la celula.
WO2008153366A3 (en) Method for manufacturing active recombinant blood coagulation factor ix

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08843082

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008843082

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12738997

Country of ref document: US